Related Experiment Video

Updated: Jan 26, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.8K

Interaction of Anticancer Drugs with Human Organic Anion Transporter hOAT4

Chenchang Liu1, Jinghui Zhang1, Guofeng You1

  • 1Departments of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, NJ, USA.

Journal of Oncology
|April 4, 2019
PubMed

Insights

Epirubicin hydrochloride and dabrafenib mesylate inhibit human organic anion transporter 4 (hOAT4). Epirubicin hydrochloride shows a high potential for drug-drug interactions via hOAT4 in the kidney, unlike dabrafenib mesylate.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Molecular Biology

Background:

  • Human organic anion transporter 4 (hOAT4) is crucial for drug disposition and drug-drug interactions.
  • hOAT4 is expressed in key organs like the kidney and placenta.
  • Individual variations in drug response are significantly influenced by drug-drug interactions.

Purpose of the Study:

  • To investigate the interaction of 36 anticancer drugs with hOAT4.
  • To determine the inhibitory effects of these drugs on hOAT4-mediated transport.
  • To assess the potential for drug-drug interactions caused by these drugs via hOAT4.

Main Methods:

  • Tested 36 anticancer drugs for cis-inhibitory effects on hOAT4 in kidney (COS-7) and placenta (BeWo) cells.
  • Determined IC50 values for identified inhibitors.
  • Performed Dixon plot analysis to elucidate inhibition kinetics (competitive vs. noncompetitive) and calculate Ki values.

Main Results:

  • Epirubicin hydrochloride and dabrafenib mesylate significantly inhibited hOAT4-mediated uptake of estrone sulfate (>50% cis-inhibition).
  • IC50 values were 5.24±0.95 μM for epirubicin hydrochloride and 8.30±3.30 μM for dabrafenib mesylate.
  • Epirubicin hydrochloride exhibited noncompetitive inhibition (Ki = 3 μM), while dabrafenib mesylate showed competitive inhibition (Ki = 4.26 μM).

Conclusions:

  • Epirubicin hydrochloride and dabrafenib mesylate are confirmed inhibitors of hOAT4.
  • Epirubicin hydrochloride has a high propensity for drug-drug interactions via hOAT4 in the kidney.
  • Dabrafenib mesylate's potential for drug-drug interactions through hOAT4 in the kidney is considered insignificant at clinically relevant exposures.

More Related Videos

Anionic Polymerization of an Amphiphilic Copolymer for Preparation of Block Copolymer Micelles Stabilized by π-π Stacking Interactions10:53

Anionic Polymerization of an Amphiphilic Copolymer for Preparation of Block Copolymer Micelles Stabilized by π-π Stacking Interactions

Published on: October 10, 2016

14.6K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
425
Cellular Membranes and Drug Transport01:24

Cellular Membranes and Drug Transport

Drugs must traverse multiple biological barriers, such as multi-layered skin, single-layered intestinal epithelium, and the plasma membrane, to reach their target sites within the body. The plasma membrane, a highly structured composite of phospholipids, carbohydrates, and proteins, is the cell's protective boundary, facilitating selective substance exchange.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
1.5K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.4K
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
307
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
228
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
576